HS 20118
Alternative Names: HS-20118Latest Information Update: 31 Mar 2025
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antipsoriatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Plaque psoriasis
Most Recent Events
- 26 Feb 2025 Preclinical trials in Psoriasis in China (PO) before February 2025
- 26 Feb 2025 Jiangsu Hansoh Pharmaceutical plans a phase I trial for Plaque psoriasis (PO) in April 2025 (NCT06846710)